Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Abbvie Inc.

Abbott Laboratories Corporation

Basf Aktiengesellschaft

Other

Abbott Gmbh & Co. Hg

Wilfried Hornberger

Helmut Mack

Wilfried Lubisch

Liliane Unger

Andreas Kling

Thorsten K Oost

Wolfgang Wernet

Charles W Hutchins

Udo Lange

Katja Jantos

Wilfried Martin Braje

Astrid Netz

Hervé Geneste

Herve Geneste

Berthold Behl

Achim Moeller

Wilhelm Amberg

Michael Ochse

Werner Seitz

Mario Mezler

Marcel Van Gaalen

Sean Colm Turner

Thomas Pfeiffer

Thomas Zierke

Daryl Richard Sauer

Margaretha Henrica Maria Bakker

Gisela Backfisch

Stefan Koser

Marjoleen Nijsen

Hans Wolfgang Höffken

Thomas Subkowski

Frauke Pohlki

Yanbin Lao

Loic Laplanche

Volker Nimmrich

Hans Wolfgang H&ouml;ffken

Achim Möller

Dorit Baucke

Arnulf Lauterbach

Dietmar Seemann

Hans-Joachim Bohm

Claudia Isabella Graef

Falko Ernst Wolter

Anil Vasudevan

Adrian Hobson

Ryan G Keddy

Nicole Teusch

Hans Wolfgang Hoeffken

Dominique Bonafoux

Carolin Hoft

Andrea Hager-Wernet, Legal Representative

Jens Sadowski

Michael F Jarvis

Wilfred Braje

Silke Weber

Hans-Joachim Boehm

Hans-Joachim B&ouml;hm

Gerd Steiner

Karsten M Wicke

Bernhard K Mueller

Martin Schmidt

Bernhard Schmied

Reinhold Mueller

Harald Bernard

Volker Laux

Juergen Delzer

Barbara Vogg

Steven Lewis Swann, Jr

Armin Beyerbach

Uta Holzenkamp

Jurgen Schweden

Elizabeth Louise Van Der Kam

Torsten Arndt

Jayne Froggett

Johann-Christian Zechel

Peter Eckes

Margaretha Bakker

Frank Oellien

Alfred Hahn, Legal Representative

Kurt Schellhaas

Juliana Ruiz Caro

Herve Genesle

Steve Swann, Jr

Dietmar Seeman

Wilfred Lubisch

Patrick Walleser

Thomas Subkoski

Claudia Krack

Jürgen Delzer

Bernhard K Muller

Jeroen Van Bergeijk

Andreas Heutling

Margaretha Henrica Bakker

Bernhard K MÜLLER

Ryan Keddy

The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Fused heterocyclic compounds as S1P modulators

The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders. 

Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders. 

Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent Rand optionally one substituent R; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R; X, X, Xand X, independently of each other, are selected from &#x2014;CH&#x2014;, &#x2014;O&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;NH&#x2014;, &#x2014;C(O)&#x2014;, &#x2014;CHCH&#x2014;, &#x2014;CHO&#x2014;, &#x2014;OCH&#x2014;, &#x2014;S(O)CH&#x2014;, &#x2014;CHS(O)&#x2014;, CHNH&#x2014;, &#x2014;NHCH&#x2014;, &#x2014;CHC(O)&#x2014; and C(O)CH&#x2014;; The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders.

Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases

The present invention relates to novel substituted oxindole derivatives of formula (I), pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders. 

Oxindole derivatives carrying an oxetane substituent and use thereof for treating vassopressin-related diseases

The present invention relates to novel fused heterocyclic or carbocyclic compounds of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising these compounds, and to their use for the treatment of vasopressin-related disorders.

Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases

The present invention relates to novel carboxamide compounds and their use as a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity and to a method for the therapeutic and/or prophylactic treatment by administering an effective amount of at least one of these carboxamide compounds. The carboxamide compounds are compounds of the general formula I in whichW&#x2014;Ris selected from and R, R, R, R, Y, Y, Y, Y, X, Q, m, k, Rand Rhave the meanings mentioned in the claims, the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y, Y, Yand Yare CR, or one or two of the variables Yto Yare a nitrogen atom and the remaining variables are CR, wherein the radicals Rmay be identical or different and have the meanings mentioned in the claims.

Carboxamide compounds and their use as calpain inhibitors

The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3&#x3b2;, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3&#x3b2; activity using the compounds.

The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R, R, R, R, R, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R, r, R, R, R, R, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH&#x2014;CH, CH&#x2014;CH&#x2014;CH, N(R)&#x2014;CH, N(R)&#x2014;CH&#x2014;CHor CH&#x2550;CH&#x2014;CH&#x2550;, each optionally having 1 or 2H-atoms replaced with identical or different radicals R, wherein Rand Rhave the meanings mentioned in the claims.

The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.

Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases

The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which

Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

The present invention relates to novel 5,6-disubstituted oxindole derivatives and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such derivatives, and to the use of such derivatives for the manufacture of a medicament, and methods of treating disorders in a subject in need thereof, such as vasopressin-dependent disorders, using 5,6-disubstituted oxindole derivatives.

5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases

The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases

The present invention relates to novel amidomethyl-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses

Growing community of inventors

Ludwigshafen, Germany

Wilfried Hornberger